sever
acut
respiratori
syndrom
sar
first
came
world
attent
march
immedi
perceiv
global
threat
pandem
potenti
help
coordin
intern
research
effort
nation
institut
allergi
infecti
diseas
conven
colloquium
entitl
sar
develop
research
respons
may
breakout
session
intend
identifi
unmet
research
need
area
sar
researchclin
research
epidemiolog
diagnost
therapeut
vaccinesar
summar
sinc
meet
howev
identifi
research
need
partial
met
need
yet
realiz
includ
reliabl
method
earli
identif
individu
sar
full
descript
sar
pathogenesi
immun
respons
anim
model
faith
mimic
sar
respiratori
symptom
also
utmost
import
global
scientif
commun
enhanc
mechan
intern
cooper
plan
sar
research
well
emerg
infecti
diseas
threat
certain
aris
futur
sever
acut
respiratori
syndrom
sar
first
sever
readili
transmiss
new
diseas
emerg
centuri
sar
case
first
observ
midnovemb
guangdong
provinc
southern
china
diseas
spread
along
intern
air
travel
rout
hanoi
hong
kong
singapor
toronto
februari
march
chain
secondari
commun
transmiss
subsequ
occur
hospit
set
affect
doctor
nurs
hospit
staff
initi
unawar
new
diseas
mode
transmiss
although
close
contact
usual
link
viral
transmiss
case
also
observ
incident
exposur
sar
immedi
perceiv
global
threat
pandem
potenti
initi
develop
nonspecif
symptom
diseas
often
progress
sever
lower
respiratori
diseas
requir
hospit
intens
care
high
casefat
rate
predictor
mortal
shown
advanc
age
casefat
year
age
underli
chronic
ill
elev
lactat
dehydrogenas
concentr
white
blood
cell
count
present
lung
patholog
specimen
reveal
hemophagocytosi
giant
cell
macrophag
origin
suggest
immun
system
play
import
role
pathogenesi
result
corticosteroid
combin
ribavirin
often
administ
treatment
albeit
limit
perceiv
benefit
march
world
health
organ
issu
global
alert
sar
support
member
intern
health
commun
author
affect
region
implement
intens
epidemiolog
surveil
rigor
adher
infectioncontrol
procedur
strict
practic
patient
isol
rigor
applic
quarantin
asymptomat
contact
aggress
restrict
travel
consequ
intern
effort
sar
outbreak
contain
midjuli
cumul
impact
limit
probabl
sar
case
fatal
despit
success
continu
vigil
indic
much
like
influenza
respiratori
pathogen
human
coronavirus
caus
common
cold
follow
winterseason
pattern
peak
late
fall
late
winterearli
spring
possibl
sar
coronaviru
cov
follow
similar
pattern
addit
current
neither
effect
treatment
sar
vaccin
prevent
infect
help
coordin
robust
research
respons
need
address
multidimension
sar
threat
nation
institut
allergi
infecti
diseas
niaid
conven
colloquium
entitl
sar
develop
research
respons
may
nation
institut
health
campu
particip
includ
physician
scientist
policymak
unit
state
canada
china
europ
elsewher
program
design
facilit
interact
among
particip
area
interest
sar
clinic
research
epidemiolog
diagnost
therapeut
vaccin
follow
section
correspond
tabl
repres
highlight
discuss
took
place
topic
conclud
discuss
recent
progress
sar
research
assess
research
need
remain
address
clinic
manifest
care
descript
clinic
manifest
sar
well
correl
longitudin
cours
diseas
clinic
virolog
immunolog
paramet
import
earli
goal
clinic
research
data
would
permit
clinic
investig
develop
standard
set
criteria
delin
progress
thu
quantifi
impact
differ
intervent
diseas
sever
moreov
systemat
correl
symptom
histolog
cytolog
virolog
immunolog
evalu
earli
late
chang
patient
sampl
would
greatli
aid
understand
sar
pathogenesi
also
import
identifi
host
viral
factor
predictor
diseas
progress
understand
role
host
genet
laboratori
surrog
would
help
improv
prognost
capabl
allow
identif
patient
like
benefit
aggress
intervent
inform
might
also
valu
develop
entri
criteria
intervent
studi
clinic
virolog
longitudin
evalu
viral
shed
use
polymeras
chain
reaction
pcr
viral
cultur
lung
gastrointestin
tract
site
would
help
patient
manag
infect
control
exampl
routin
find
infecti
viru
stool
week
resolut
clinic
ill
would
like
chang
recommend
regard
isol
data
would
also
provid
inform
site
viru
replic
show
whether
evolv
cours
ill
previou
studi
anim
coronaviru
infect
shown
small
chang
viral
envelop
protein
dramat
effect
tissu
tropism
clinic
manifest
exampl
singl
amino
acid
chang
spike
protein
chang
transmiss
gastroenter
viru
predominantli
respiratori
pathogen
intestin
pathogen
reason
evalu
viral
quasi
speci
obtain
differ
tissu
obtain
patient
differ
clinic
manifest
sar
obtain
time
singl
patient
could
reward
error
rate
transcript
coronaviru
rnadepend
rna
polymeras
typic
order
similar
rate
revers
transcriptas
high
rate
like
caus
substanti
variat
viral
genom
occur
time
could
permit
drugresist
isol
emerg
care
surveil
develop
drugresist
sar
strain
therefor
part
antivir
research
protocol
clinic
immunolog
import
thoroughli
understand
cellular
humor
immun
respons
sar
viru
includ
impact
sar
immun
function
immunopatholog
respons
viru
may
engend
studi
relationship
specif
immun
respons
subsequ
clinic
cours
would
help
identifi
correl
protect
immun
would
turn
great
valu
develop
vaccin
immunebas
therapi
immunosuppress
element
describ
coronaviru
infect
examin
effect
sar
abil
host
gener
immun
respons
antigen
indic
research
done
studi
immun
respons
recal
antigen
tetanu
toxoid
primari
antigen
bacteriophag
phi
x
interpret
studi
must
clearli
distinguish
effect
specif
sar
viru
infect
gener
seriou
ill
better
understand
role
immun
system
sar
pathogenesi
critic
would
help
develop
new
therapeut
strategi
deleteri
respons
may
specif
case
crossreact
autoantibodi
nonspecif
overli
robust
inflammatori
respons
sever
lymphopenia
describ
patient
sar
remain
mysteri
could
relat
immun
mechan
detail
studi
bone
marrow
function
lymphocyt
kinet
individu
sar
may
yield
import
clue
caus
anemia
intern
collabor
global
network
research
center
form
test
therapeut
approach
develop
help
conduct
basic
clinic
research
describ
sar
clinic
center
must
locat
countri
sar
occur
must
cooper
local
commun
must
also
appropri
equip
must
access
requisit
scientif
expertis
includ
clinic
trial
design
pharmacolog
data
manag
extent
possibl
protocol
trial
therapi
develop
advanc
need
trial
must
design
test
new
antivir
drug
antibodi
therapi
immunomodulatori
approach
use
corticosteroid
trial
must
test
applic
therapi
treatment
symptomat
patient
postexposur
prophylaxi
see
therapeut
discuss
therapeut
develop
anim
reservoir
sar
cov
almost
certainli
zoonot
origin
coronavirus
broad
host
rang
avian
mammalian
speci
initi
sar
case
guangdong
provinc
occur
among
worker
food
prepar
restaur
industri
suggest
practic
associ
liveanim
market
region
sourc
human
infect
moreov
worker
liveanim
market
shenzhen
china
show
serolog
evid
sar
cov
infect
without
histori
sarslik
ill
virolog
surveil
liveanim
market
led
isol
coronavirus
close
relat
sar
cov
studi
genet
divers
relat
coronavirus
broad
rang
wild
domest
anim
may
help
identifi
potenti
anim
reservoir
sar
cov
well
virolog
environment
characterist
favor
zoonot
transmiss
natur
histori
littl
known
natur
histori
sar
cov
infect
also
critic
reproduct
rate
r
quantifi
differ
subpopul
set
climat
initi
estim
suggest
r
consider
less
highli
transmiss
virus
influenza
viru
r
may
chang
season
rel
small
chang
may
determin
whether
viru
becom
establish
human
popul
moreov
effect
host
factor
especi
age
viral
transmiss
remain
clarifi
children
infect
sar
cov
experi
much
less
sever
ill
wherea
peopl
year
age
suffer
sever
diseas
high
mortal
howev
yet
clear
probabl
viral
transmiss
vari
among
age
group
similarli
preval
asymptomat
infect
possibl
transmiss
oralfec
rout
blood
transfus
presenc
host
genet
factor
affect
suscept
yet
determin
final
viral
host
environment
factor
caus
socal
superspread
incid
mani
peopl
infect
singl
individu
elucid
quickli
possibl
infectioncontrol
strategi
current
avail
strategi
control
sar
isol
quarantin
procedur
need
address
sar
emerg
infecti
agent
social
psycholog
consequ
isol
quarantin
studi
incent
peopl
adher
implement
polici
assess
efficaci
infectioncontrol
techniqu
screen
febril
passeng
airport
also
examin
intern
collabor
experi
sar
underscor
need
establish
collabor
intern
diseas
surveil
research
network
especi
southeast
asia
march
rapidli
establish
global
network
sar
research
center
model
network
influenza
surveil
research
center
alreadi
place
help
facilit
isol
identif
sar
cov
complet
genom
sequenc
multipl
isol
ultim
intern
support
onsit
collabor
network
allow
rapid
exchang
inform
reagent
among
skill
profession
therefor
enhanc
research
sar
emerg
infecti
diseas
threat
beyond
establish
collabor
center
utmost
import
scientist
worldwid
share
avail
epidemiolog
data
regard
sar
analys
pool
data
affect
countri
adequ
clarifi
complex
issu
role
super
spreader
diarrhea
factor
affect
transmiss
identif
risk
factor
sever
diseas
outcom
benefit
variou
treatment
strategi
establish
databas
link
epidemiolog
clinic
laboratori
data
individu
sar
worldwid
would
therefor
tremend
benefit
winter
month
diagnost
challeng
differenti
sar
infect
especi
great
mean
essenti
develop
diagnost
assay
differenti
sar
cov
respiratori
pathogen
rapidli
simpli
precis
also
import
develop
diagnost
test
diseas
specif
rapidli
recogn
presenc
known
novel
pathogen
serolog
assay
sar
cov
initi
identifi
use
cell
cultur
inocul
passag
follow
electron
microscopi
genom
sequenc
analysi
standard
elisa
neutral
test
immunofluoresc
antibodi
assay
develop
immedi
thereaft
use
test
demonstr
individu
sar
develop
specif
antibodi
viru
crossreact
human
coronavirus
present
wide
popul
serolog
test
wide
avail
countri
activ
sar
cov
transmiss
occur
igg
antibodi
howev
appear
least
day
infect
igm
antibodi
typic
appear
earlier
igm
captur
assay
develop
similarli
measur
sar
covspecif
iga
antibodi
rapid
test
design
use
oral
fluid
could
prove
use
pcr
assay
first
complet
genom
sequenc
sar
cov
avail
within
week
initi
global
alert
distinct
isol
sinc
deposit
genom
databas
avail
sar
nucleotid
sequenc
allow
rapid
develop
standard
reversetranscriptas
pcr
assay
detect
sar
cov
rna
respiratori
secret
lung
kidney
tissu
stool
urin
specimen
pcr
assay
exquisit
sensit
detect
limit
copi
target
rna
howev
presenc
viral
rna
necessarili
indic
presenc
infecti
viru
method
except
sensit
may
lead
falseposit
result
crosscontamin
factor
continu
work
standard
perform
pcr
assay
sar
determin
optim
protocol
remain
high
prioriti
reagent
repositori
reagent
infecti
viru
viral
rna
inactiv
recombin
antigen
sar
covspecif
polyclon
monoclon
antibodi
essenti
tool
develop
diagnost
assay
wellvalid
clinic
specimen
individu
sar
global
public
health
author
therefor
continu
coordin
collect
storag
distribut
materi
perhap
exist
new
collabor
research
center
altern
niaid
might
consid
includ
materi
reagent
repositori
plan
support
assay
nonhuman
primat
smallanim
model
develop
bioterror
threat
agent
moreov
initi
develop
diagnost
assay
reagent
also
done
use
specimen
anim
model
improv
model
continu
antivir
drug
screen
although
antivir
chemotherapi
prophylaxi
great
import
control
sar
clinic
proven
candid
current
exist
work
collabor
unit
state
armi
medic
research
institut
infecti
diseas
niaid
center
diseas
control
prevent
establish
sar
antivir
drugscreen
laboratori
march
assay
use
laboratori
measur
much
candid
compound
inhibit
cytopath
effect
sar
cov
grow
cultur
vero
cell
initi
antivir
drug
screen
includ
us
food
drug
administr
approv
clinic
develop
preclin
data
suggest
activ
potenti
viral
target
protein
vitro
activ
sar
cov
observ
certain
prepar
interferona
b
well
rimantadin
high
concentr
cystein
proteas
inhibitor
antivir
drug
design
molecular
virolog
genet
studi
sar
cov
coronavirus
suggest
sever
possibl
molecular
target
antivir
drug
includ
viral
bind
fusion
activ
mediat
glycoprotein
spike
coronaviru
surfac
well
viral
rnadepend
rna
polymeras
papainlik
cystein
proteas
chymotrypsinpicornaviru
proteas
inhibitor
surfac
hemagglutininesteras
activ
involv
releas
viru
cell
surfac
may
also
repres
class
use
antivir
drug
molecular
model
drug
design
strategi
continu
pursu
develop
compound
modul
viral
activ
immunomodul
therapi
avail
clinic
histopatholog
data
suggest
immunemedi
injuri
may
import
mechan
sar
pathogenesi
particularli
late
cours
ill
thu
would
use
assess
use
immunomodulatori
drug
corticosteroid
either
combin
antivir
effect
administr
immunoglobulin
neutral
activ
sar
cov
therapi
prophylaxi
also
examin
preclin
studi
nonhuman
primat
smallanim
model
need
sar
antivir
drug
develop
mous
hepat
viru
group
ii
murin
coronaviru
well
character
mice
may
prove
use
regard
although
may
differ
significantli
sar
cov
may
end
prove
necessari
develop
sever
model
address
differ
aspect
pathogenesi
sar
system
versu
respiratori
tract
infect
niaid
also
strengthen
abil
produc
suffici
suppli
promis
experiment
compound
conduct
preclin
toxicolog
studi
continu
expand
biocontain
laboratori
facil
shortag
significantli
inhibit
antivir
develop
collabor
us
food
drug
administr
antivir
drug
develop
occur
earli
stage
develop
process
assess
preclin
data
plan
clinic
studi
clinic
trial
network
niaid
collabor
antivir
studi
group
casg
expand
strengthen
particularli
includ
site
countri
sar
occur
collabor
clinic
protocol
prepar
casg
develop
clinic
protocol
could
use
templat
establish
collabor
studi
clinic
protocol
look
diseas
progress
also
titer
excret
viru
durat
excret
probabl
marker
likelihood
transmiss
basic
scienc
sar
emerg
mani
import
basic
scienc
issu
yet
fulli
explor
includ
ident
cellular
receptor
viru
pathogen
mechan
caus
diseas
initi
rout
infect
role
enter
infect
play
pathogenesi
transmiss
immunolog
issu
warrant
intens
studi
includ
rel
role
innat
adapt
immun
detail
descript
immunolog
respons
throughout
cours
diseas
whether
patient
immun
reinfect
recoveri
immun
system
chang
might
confer
immun
experi
date
indic
immun
respons
might
play
role
sar
pathogenesi
import
implic
treatment
vaccin
develop
encourag
use
vaccin
anim
coronavirus
mous
hepat
viru
develop
use
variou
strategi
includ
liveattenu
wholekil
subunit
approach
howev
experiment
vaccin
base
strategi
direct
felin
infecti
periton
viru
enhanc
diseas
immun
anim
crucial
therefor
immun
respons
contribut
diseas
identifi
soon
possibl
sar
vaccin
candid
evalu
possibl
might
potenti
diseas
vaccin
develop
given
need
quick
develop
safe
effect
sar
vaccin
multipl
strategi
vaccin
develop
pursu
simultan
includ
develop
liveattenu
wholekil
vaccin
candid
addit
strategi
elicit
strong
cell
respons
dnabas
vaccin
engin
adenoviru
vector
well
elicit
product
neutral
antibodi
adjuv
confer
longerliv
protect
mucos
system
immun
respons
also
pursu
final
subunit
vaccin
base
protein
fragment
peptid
epitopebas
cell
vaccin
formul
new
adjuv
target
tolllik
receptor
also
develop
preclin
test
anim
model
sar
cov
infect
need
test
safeti
efficaci
candid
vaccin
reagent
repositori
research
could
obtain
recombin
viral
protein
multipl
spike
protein
monoclon
antibodi
plasmid
immun
control
patient
sera
would
extrem
help
would
molecular
immunolog
databas
contain
descript
b
cell
epitop
sar
cov
genom
data
move
candid
sar
vaccin
rapidli
scientif
regulatori
evalu
requir
coordin
effort
govern
academ
industri
organ
group
work
togeth
identifi
potenti
barrier
product
licens
cooper
develop
plan
widespread
test
deploy
promis
vaccin
prepar
countri
sar
exist
first
wave
sar
control
vigor
intern
applic
timetest
techniqu
isol
quarantin
intern
research
respons
forc
cooper
short
order
viru
caus
sar
identifi
sequenc
firstgener
diagnost
test
develop
distribut
develop
antivir
therapi
vaccin
initi
much
progress
achiev
intern
network
research
site
built
larg
preexist
influenza
network
reflect
astonishingli
rapid
pace
sar
research
niaid
meet
summar
great
mani
fundament
insight
sar
describ
occur
week
initi
global
health
alert
progress
sar
research
continu
even
first
wave
diseas
subsid
sever
identifi
research
need
least
partial
met
exampl
vitro
screen
antivir
candid
sar
cov
move
acceler
pace
result
recent
introduct
highthroughput
assay
screen
compound
per
week
addit
mani
sar
vaccin
candid
develop
around
world
preliminari
result
test
mice
nonhuman
primat
indic
neutral
antibodi
protect
vaccin
candid
elicit
neutral
antibodi
may
shortli
enter
human
trial
token
howev
sever
need
cut
across
variou
field
sar
research
remain
unfulfil
tabl
although
progress
report
mani
area
well
press
need
describ
method
earli
identif
individu
sar
mani
pcr
serolog
diagnost
kit
avail
diagnost
tool
develop
exist
report
realtim
pcr
coupl
improv
rna
extract
method
allow
detect
viral
rna
nasopharyng
aspir
specif
consider
improv
firstgener
procedur
research
made
possibl
avail
set
wellcharacter
clinic
sampl
individu
confirm
sar
coupl
match
control
rigor
test
diagnost
procedur
use
standard
sampl
remain
challeng
intern
commun
howev
addit
complet
understand
bodi
viru
found
differ
stage
diseas
might
lead
new
diagnost
strategi
exampl
report
sar
cov
replic
peripher
blood
mononuclear
cell
individu
sar
shortli
onset
symptom
indic
blood
might
appropri
clinic
specimen
diagnosi
avail
highli
accur
specif
diagnost
assay
could
detect
sar
cov
shortli
onset
symptom
would
tremend
valuabl
public
health
tool
futur
sar
outbreak
sar
pathogenesi
immun
respons
complet
understand
sar
pathogenesi
togeth
full
pictur
human
immun
respons
yet
achiev
regard
particularli
import
understand
role
human
immun
respons
play
sever
diseas
outcom
recent
report
describ
chang
cytokin
concentr
patient
seroposit
sar
cov
beij
earli
peak
recoveri
stage
diseas
indic
immun
system
respond
abnorm
viru
kind
studi
provid
use
insight
pathogen
mechan
effect
experiment
therapi
anoth
report
indic
angiotensinconvert
enzym
function
receptor
sar
cov
work
systemat
unravel
aspect
sar
cov
interact
human
host
molecular
physiolog
level
help
ensur
rapid
develop
therapeut
techniqu
diagnost
assay
vaccin
sar
anim
model
shown
viru
replic
sever
small
anim
includ
mask
palm
civet
raccoon
dog
mice
domest
cat
nonhuman
primat
research
varieti
anim
model
choos
develop
vaccin
therapeut
strategi
reli
sever
differ
model
advantag
differ
experiment
set
howev
anim
model
describ
date
reliabl
mimic
respiratori
symptom
seen
human
sar
recent
report
indic
sarsinfect
ferret
becom
ill
although
anim
show
evid
pneumonia
followup
work
anim
might
lead
discoveri
anim
model
reproduc
sar
symptom
human
enhanc
mechan
intern
cooper
access
wellcharacter
specimen
reagent
still
limit
factor
mani
avenu
sar
research
although
progress
made
moreov
increas
compil
analysi
exist
epidemiolog
laboratori
clinic
data
multipl
sarsaffect
area
would
speed
research
exampl
singl
site
suffici
number
superspread
event
provid
enough
data
complet
explain
howev
data
pool
mani
site
differ
countri
would
provid
much
greater
chanc
explain
import
phenomenon
similarli
data
success
failur
variou
treatment
strategi
alreadi
attempt
rigor
compar
analyz
final
although
protocol
clinic
test
therapeut
vaccin
candid
prepar
common
protocol
implement
across
multipl
intern
site
data
acquir
trial
made
wide
avail
acquir
combat
sar
intern
public
health
commun
must
effect
har
experi
creativ
talent
laboratori
scientist
public
health
worker
physician
health
care
worker
world
although
intens
effort
exert
first
month
control
initi
outbreak
must
lull
fals
sens
secur
pandem
potenti
sar
novel
agent
transmit
via
respiratori
secret
remain
present
today
serv
remind
emerg
pathogen
whether
natur
intent
devast
human
econom
cost
reason
plan
effort
futur
pandem
must
suffici
flexibl
cope
emerg
respiratori
viru
perform
research
need
effect
counter
sar
requir
continu
global
invest
human
financi
resourc
ongo
commit
collabor
share
data
materi
